bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.5271 +0.2071 (+64.72%)

Delayed Quote Updated: 11:33 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Warrant

< Previous 1 2 3 4 Next >

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

September 30, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

September 22, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

September 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

September 09, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 03, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

September 01, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

August 20, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

August 18, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

August 14, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

August 13, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

August 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

July 27, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

July 22, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

July 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

June 22, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $3.2 Million Offering

June 18, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

June 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans

June 16, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

June 02, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology

May 27, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

May 12, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung

May 08, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

April 28, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

April 14, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

April 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

April 01, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

March 25, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

March 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

March 13, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

March 10, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.